Extramedullary disease (EMD) at diagnosis in patients with acute myeloid leukemia (AML) has been recognized for decades. Reported herein are results from a large study of patients with AML who were treated in consecutive ECOG-ACRIN Cancer Research Group frontline clinical trials in an attempt to define the incidence and clinical implications of EMD.
INTRODUCTION
One of the known manifestations of acute myeloid leukemia (AML) is extramedullary disease (EMD). The overall incidence of EMD reported in the literature is not clearly established, ranging from 2.5% 1 to 30%, 2 and varies among different types of AML; patients with monocytic AML 3 and those with t(8;21) 4, 5 have a relatively higher incidence. The prognostic impact of EMD is unfavorable in some reports 2, 5 but not in others. [6] [7] [8] Reports on the prognosis of specific EMD sites, such as the CNS, are also contradictory. 9, 10 The current analysis evaluated a large cohort of patients with newly diagnosed AML from 11 consecutive clinical trials conducted by the ECOG-ACRIN Cancer Research Group. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The objectives were to describe the demographic, clinical, and biologic characteristics of patients with newly diagnosed AML with EMD and to evaluate how the presence, extent, and characteristics of EMD may affect response to treatment and outcome.
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Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article. Between 1980 and 2008, 3,522 patients age 15 years and older with  untreated AML were enrolled in 11 consecutive, phase II and III, ECOG-ACRIN-led clinical trials. 11-20 The treatment protocols, their activation dates, and accrual numbers are summarized in Table 1 .
METHODS

Patient Population
Patients were excluded from the current analysis if they had a diagnosis other than AML, had no documented EMD ascertainment at baseline, withdrew from the study before treatment had begun, or had no survival follow up. Patients with acute promyelocytic leukemia were included in the older AML studies but are excluded from the analysis as a result of the unique behavior and treatment of this disease. Each protocol was approved by an institutional review board. All patients signed a written informed consent.
Cytogenetic Risk Classification
Cytogenetic The unfavorable risk category was defined by the presence of one or more of 25/del(5q); 27/del(7q); inv(3q)/t(3;3); deletion 20q or 21q; translocation involving 11q23, t(6;9); t(9;22); deletion 17p; or complex karyotype, defined as three or more chromosomal abnormalities. Minimal cytogenetic information was available for patients enrolled in the following earlier protocols: E1479, E1490, E3480, E3483, or PC486.
Flow Cytometry
The diagnosis of AML was confirmed by multiparameter flow cytometry for patients in protocols E3489, E1490, E3993, E3997, E4995, PC486, E3999, and E1900. Three adhesion molecules (CD11a, CD11b, and CD56) were evaluated for their association with EMD.
EMD Assessment and Treatment
In all 11 trials, bone marrow (BM) leukemic involvement was an eligibility criterion; thus patients with an isolated extramedullary myeloid sarcoma without BM involvement are not included. The presence of EMD was recorded at baseline. EMD in these studies was defined clinically by physical examination and radiology without necessarily requiring a biopsy. A lumbar puncture (LP) was mandatory (five trials), recommended for patients with high blast count (two trials) or if CNS signs or symptoms were present (three trials).
The treatment of CNS involvement was on the basis of intrathecal methotrexate in seven trials, high-dose cytarabine in two trials where this was part of the induction protocol, or physician's choice.
Individual EMD sites were first evaluated as a whole group, then separately by site and finally, by classifying them as three organ-based subgroups: hematopoietic (lymph nodes [LNs], spleen, or liver), nonhematopoietic (skin or gingiva with or without EMD in hematopoietic sites), and rare areas of involvement (CNS, bone, lung, or myeloid sarcoma with or without EMD in previous sites).
Hematopoietic Stem-Cell Transplantation
Among the 11 studies, hematopoietic stem-cell transplantation (HSCT) was part of the treatment regimen in five (E3483, E3489, PC486, E4995, and E1900), and patients were classified according to the type of transplantation received. In most cases, HSCT was done as part of protocol treatment. However, if a patient's record had a definitive comment indicating that the patient received HSCT off-protocol, this information was applied. All other patients were classified as no transplantation.
Statistical Analysis
Descriptive statistics were used to characterize patients and their disease. A t test was used to explore potential differences in continuously parameterized disease and patient characteristics between patients with and without EMD. x 2 tests or Fisher's exact tests were used to test for differences in categorical features. A two-sided P value of .05 was considered statistically significant for these tests.
Univariable analyses of potential prognostic factors were done. The method of Kaplan and Meier was used to estimate median overall survival (OS) within each prognostic category. Differences were assessed using a one-sided log-rank test. Cox proportional hazards models were used to examine the effect of one-unit increases in continuous variables on OS.
Multivariable models were built using backward selection. First, factors (or groups of factors) significant at the .10 level in univariable analyses were included in the model. Factors were dropped one at a time by comparing Abbreviations: allo, allogeneic; ARA-C, cytarabine; auto, autologous; BMT, bone marrow transplantation; CR, complete remission; d, day; DAT, daunorubicin plus ARA-C plus 6-TG; dauno, daunorubicin; GM-CSF, granulocyte-macrophage colony-stimulating factor; GO, gemtuzumab ozogamicin; HSCT, hematopoietic stem-cell transplantation; IV, intravenous; mitox, mitoxantrone; PBSCT, peripheral blood stem-cell transplantation; PO, orally; rhIL-11, recombinant human interleukin 11; SC, subcutaneous; 6-TG, thioguanine.
nested models using the Schwarz-Bayesian criterion and 22 log-likelihood. The final model is the one that minimized these criteria. To minimize the effect of missing data, indicator variables for missing values were included.
RESULTS
Incidence and Sites
Of the 3,522 enrolled patients, 282 were excluded, because of diagnosis of acute promyelocytic leukemia (n = 168) or leukemia other than AML (n = 29), no EMD evaluation at baseline (n = 41), retrospective central review ineligibility (n = 24), or no survival data (n = 20 (9.5%) had three sites, 26 (3.4%) had four sites, and seven (0.9%) had five or six sites.
EMD Assessment
There were several versions of case report forms in use over the time interval, and the diagnosis method was characterized in four different ways. In general, multiple methods of diagnosis were not captured. Among 308 extramedullary sites identified for studies E1479 and E3480, 89.6% were identified by physical examination, 2.6% by biopsy, and 7.8% by other, which included x-ray, scan, or chemical means. For no other studies was there a distinction between physical examination and imaging as a basis for diagnosis. There were 92 distinct sites noted on study E3999, 94.6% by being clinically involved and 5.4% by being pathologically involved. For study E1900, no details about the method of diagnosis were captured. For all other studies, among 735 distinct sites, 92.9% were diagnosed clinically and 7.1% pathologically. Thus, the vast majority (. 90%) were diagnosed by physical examination rather than by biopsy, but the role of scans is unclear (Appendix Table A1 , online only).
Characteristics of Patients With EMD
Patients with EMD, compared with those without EMD, were younger (median age, 45.7 v 52.9 years; P , .001) and males (57.9% v 52%; P = .006). They had a poorer performance status (PS; 76.4% with Eastern Cooperative Oncology Group PS 0-1 v 86%; P , .001) and higher WBC count (median, 41.6/mL v 10.2/mL; P , .001). The median percentage of blasts in the BM and in the peripheral blood was higher in the EMD group. Other characteristics did not differ significantly by EMD status (Tables 2 and 3) .
FAB Category and EMD
The proportion of patients classified as French-AmericanBritish (FAB) M4 and M5 was higher among those with EMD (39% and 15.9%, respectively) compared with others (26% and 6.8%, respectively). In every EMD subgroup, the most common FAB category was M4 (approximately 40% of the patients in every subgroup, compared with 26% of the non-EMD patients). Among 815 patients with FAB M2, 15.6% had EMD and among the 98 patients with recorded t(8;21), only 10.2% had EMD.
Responses
The complete remission (CR) rate for all patients was 59.7% and was similar for patients with or without EMD (59% and 60%, respectively). The CR rate was similar for patients with individual EMD sites except for those with splenic and gingival involvement, who had a nonsignificant lower CR rate compared with the whole cohort (P = .06 and .08, respectively).
Survival
The median OS was 1.035 years. There were 2,625 deaths among the 3,240 patients included in the analysis. In univariable analysis (Table 4) , EMD was associated with a shorter OS (P = .005; Fig 1A) . Among individual EMD sites, the analysis revealed that skin (P = .002), spleen (P , .001; Fig 1B) , and liver (P , .001), but not CNS (P = .34; Fig 1C) , nodal involvement (P = .94), and gingival hypertrophy (P = .24), were associated with shorter OS.
A greater number of EMD-involved sites, both as a categorical variable (1 v $ 2) and as a continuous variable, was negatively associated with OS (P = .002 and P , .001, respectively). Each additional site of EMD conferred a 9.5% increase in the risk of death. Among EMD subgroups (hematopoietic, nonhematopoietic, and rare), the rare areas of involvement had an OS advantage compared with the other two subgroups (median OS of 12.4 v 11.2 and 10.9 months, respectively; P = .01).
Parameters associated with longer OS were good PS, female sex, M2 FAB category, favorable cytogenetic risk group, undergoing HSCT, achieving CR postinduction, younger age, later year of registration, lower WBC count at diagnosis, higher platelet count, and low percentage of blasts in the BM.
A multivariable model (Table 5 ) was constructed to examine the effect of EMD on OS after adjusting for known prognostic factors. Earlier year of registration, older age, high WBC count, low platelet count, worse PS (compared with Eastern Cooperative Oncology Group PS 0), high cytogenetic risk status, and not achieving a CR were associated with shorter OS. Neither the presence of EMD, the number of extramedullary sites, nor any EMD-specific site, including the CNS, contributed prognostic significance to the multivariable models. 
EMD Throughout the Years of Registration
The year of registration was found to be a significant statistical variable in most of the different multivariable models that were performed (P = .043 to , .001). Among patients registered before 2002, the presence of EMD did not affect OS. Patients enrolled before 1990 had median survival of approximately 12.5 months and it was 12.8 months among those enrolled between 1990 and 1999, regardless of EMD status. Among patients enrolled after 2002, survival continued to improve over time among patients without EMD (median survival, 14.1 months; P , .001), but not among patients with EMD (median survival, 8.3 months; P = .353). The negative impact of EMD on outcome was seen predominantly among older patients with EMD enrolled in E3999, but not with younger patients enrolled in E1900 during the same time period.
EMD and Cytogenetics
Cytogenetic data were available in 49% of the study cohort. Of these, 200 patients had known favorable cytogenetics, and EMD was present in only 26 patients (13%). No significant difference in OS was found between the groups, but the numbers are too small for a definitive assessment (Fig 1D) . The incidence of EMD among those patients with other than favorable cytogenetics was 15.1%, similar to that in patients with favorable cytogenetics. Although both the presence of EMD and other than favorable cytogenetic risk were significant predictors of poor survival (by pairwise survival estimates and hazard ratios) compared with no-EMD and favorable cytogenetic risk, respectively, the interaction of these factors was not significant (P = .61).
EMD and Adhesion Molecules
There was a higher incidence of CD11b-positive AML among patients with EMD (29%) than patients without EMD (9%; P , .001). The percentage of CD11a and CD56-positive blasts was comparable between the two groups.
EMD and HSCT
Data about transplantation, in studies where this was not part of the protocol, are limited. The percentage of patients who underwent a transplantation was slightly lower among the EMD group compared with the others (14.7% v 18%, respectively; P = .07). The median OS of the 446 patients who underwent HSCT was 40.6 months, compared with 9.4 months of the 2,152 patients who did not (P , .001). Nevertheless, undergoing transplantation was not found to be a significant variable in a multivariable analysis.
DISCUSSION
On the basis of data from 11 consecutive ECOG-ACRIN clinical trials, the presence of EMD at diagnosis does not have independent prognostic value. This observation is clinically meaningful, given that the incidence of EMD in adults with newly diagnosed AML was approximately 24%. The rate of EMD reported in the literature has a broad range related to definitions and method of evaluation. Some define EMD as organ involvement, not including liver, spleen, and LNs. 6 Using the terms myeloid sarcoma or chloroma, some imply a discrete mass of myeloblasts, not including cases of organ infiltration. 1 We and others 2 used clinical assessment of EMD without requiring a biopsy, whereas others established the diagnosis of EMD only if pathologically confirmed. 1, 23 LNs, spleen, and gingiva are likely to be considered as EMD sites by physical examination, but usually would not be biopsied and therefore not be considered as pathologically proven EMD. With more sensitive diagnostic tools, such as positron emission tomography (PET), the rate of presumed EMD at diagnosis is likely to be even higher.
24 For example, in 26 patients with newly diagnosed AML, Cribe et al 25 demonstrated that 18 F-labeled fluorodeoxyglucose PET testing doubled the rate of EMD, from 31% by clinical examination to 65%. It is possible that many patients with AML have clusters of leukemic cells in different organs, in addition to the blood and marrow, and the only question is the resolution of the test used for assessment. However, it is neither ethical nor practical to biopsy every suspected EMD site, and it would be prohibitively costly to perform PET-computed tomography for every patient with AML. Therefore, despite its limitations, clinical evaluation remains the main assessment method for EMD in routine practice.
To the best of our knowledge, this is the largest study of EMD with information on the distribution of EMD among different sites. LNs and spleen were the most common sites reported, with incidences of 11.5% and 7.3%, respectively, followed by liver (5.3%), skin (4.5%), and gingiva (4.4%), whereas CNS involvement was observed in only 1.1%. The low incidence of CNS involvement is the only variable that is consistent in early studies 24, 26 as well as contemporary studies. 27 Rozovski et al 9 recently reported a 3.3% incidence of CNS involvement among 1,412 patients with newly diagnosed AML who did not undergo a routine LP compared with 19% of 42 patients who underwent a routine LP. We did not observe such a difference; therefore, the rarity of the reported CNS involvement supports not performing a routine LP in patients with AML unless neurologically indicated.
The number of involved sites is usually not reported in the literature. In our study, 35% of patients with EMD had more than one involved site; 9.5% had three sites and some patients even had five and six involved sites. The relatively high rate of multiple-site EMD involvement suggests that the development of EMD is an intrinsic feature of the leukemic cells and depends on factors such as the expression of cell surface adhesion molecules. 2, 28 In our cohort, the median percentage of CD11b-positive blasts was significantly higher among the patients with EMD but, in contrast to the report by Chang et al, 2 CD56 was not. In the multivariable model, earlier year of registration, older age, high WBC count, low platelet count, poor PS, high cytogenetic risk status, and not achieving a CR were associated with a shorter OS. However, EMD as a group, as well as every individual EMD site, had no independent effect on prognosis. It is possible that individual sites of EMD are in fact associated with poorer prognosis; however, these patients also have other unfavorable prognostic factors, such as high WBC count and unfavorable cytogenetics, whereas EMD has no independent prognostic effect. Indeed, patients with EMD, in this series and in others, 2,29,30 had higher WBC Overall Survival (probability) Overall Survival (probability)
Overall Survival (probability)
No ( www.jco.org counts at diagnosis. The similar outcome of patients with CNS involvement to others may also be explained in a different way. CNS is the only EMD site that mandates a specific therapeutic approach, intrathecal methotrexate and/or high-dose cytarabine, which may overcome the potential negative effect of CNS involvement.
The median age of the patients was 51.1 years. Patients with EMD, compared with those without EMD, were younger (median age, 45.7 v 52.9 years; P , .001). There was a statistically significant decline in the incidence of extramedullary disease with increasing age, and a statistically significant decline in survival with increasing age among patients both with and without EMD. Nevertheless, the interaction of age-by-EMD status was not statistically significant, so the effect of age on survival was similar in both groups (Appendix Table A2 , online only).
We classified the patients with EMD into three subgroups: hematopoietic organs (lymph nodes, spleen, or liver), nonhematopoietic organs (skin or gingiva with or without EMD in hematopoietic sites), and rare areas of involvement (CNS, bone, lung, or myeloid sarcoma with or without EMD in previous sites). The rationale for this division was that every subgroup might develop in a different context. The first subgroup is probably influenced by the time from first symptoms to diagnosis and treatment of AML. The second depends on specific subtypes of AML, mainly those with a monocytic component. 3 The third subgroup is composed of rare sites and the context of development is unknown. Interestingly, the third group had better survival compared with the two others.
By stratifying patients with available cytogenetic data (approximately 50% of the cohort) into favorable and other than favorable cytogenetics, we thought that the effect of EMD on prognosis might appear significant, particularly in the patients with favorable cytogenetics. Indeed, the median OS among the favorable cytogenetic group was 32.9 versus 94.2 months, with and without EMD, respectively (Fig 1D) . However, the number of patients was small and the difference was not significant (P = .145). Nevertheless, the question of the effect of EMD among patients with favorable cytogenetics needs to be studied in larger cohorts.
In conclusion, this large study demonstrates that EMD is more common than previously reported and frequently occurs in multiple sites, although CNS involvement is rare. Perhaps surprisingly, EMD at presentation does not have independent prognostic significance. Importantly, the presence of EMD should not affect the choice of postremission therapy.
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